Track the NovaBridge Biosciences stock price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €212.8m. The latest transaction was reported on 8 September 2026 (Levée d'options). Among the most active insiders: Xu Cong Claire. The full history is openly available.
10
Insider Decl.
n/a
Thresholds
€494,100
1 ops.
Buy Volume
€5,726
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate NovaBridge Biosciences Strong Buy (bullish), based on 4 analysts. Average price target: US$8.25.
27Σ signal
Buys €494,100€5,726 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
230,000 shares@ US$2.510.24% mcap100.0% of flowOrdinary SharesSEC:0001193125-26-186924:0
Canonical exit: 23 Jul 2026 (T+90)
10 of 10 declarations
About NovaBridge Biosciences
NovaBridge Biosciences is a company listed on the XNAS market, specializing in the development of innovative biopharmaceutical solutions. It focuses on research and commercialization of treatments for complex diseases.